Genzyme Hits Impax With IP Suit Over Renagel ANDA
Biotechnology company Genzyme Corp. has filed its second patent infringement lawsuit this month to block a generic version of the drug Renagel, this time targeting California-based generics maker Impax Laboratories Inc....To view the full article, register now.
Already a subscriber? Click here to view full article